Updated

Robert F. Kennedy Jr. has reportedly proposed that the FDA relax its regulatory scrutiny of unproven peptide drugs, according to reporting on his policy recommendations. FDA scientists have indicated that none of the popular peptide medications in question have been proven safe or effective, raising questions about the regulatory implications of such a policy shift.